|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
Therapy Tidbits Winter 2021
Therapy Tidbits –Winter 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Winter 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
*Pandemic Spurs Interest in Walk-and-Talk Therapy – Introduces the idea of ‘Walk and Talk’ therapy sessions, highlighting the pros and cons of such sessions.
*Cybersecuri... |